Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma | MicrobiomeTrials← Back to trialsNCT04015700
Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2020-07-14Est. Completion: 2022-05-13
Enrollment target: 9 participants Locations- Washington University School of Medicine, St Louis, Missouri, United States
Other microbiome trials you might be interested in
Newly Diagnosed GlioblastomaMGMT-Unmethylated Glioblastoma
The Primary Objective of this study is to evaluate the efficacy and safety of teniposide in combination with temozolomid…
Multiple LocationsEst. completion Mar 2030
GlioblastomaGliosarcomaGBMGlioblastoma MultiformeGlioblastoma, IDH-wildtypeRecurrent Glioblastoma
Paclitaxel is among the most active agents against glioblastoma in preclinical models. However, its clinical use has bee…
Chicago, United StatesEst. completion Dec 31, 2027
Glioblastoma, IDH-Wildtype
This phase II trial compares the effect of adding WSD0922-FU to temozolomide versus temozolomide alone in slowing diseas…
Scottsdale, United StatesEst. completion Aug 31, 2036